https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41167 Wed 21 Jun 2023 15:55:59 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54623 Wed 06 Mar 2024 10:51:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49876 3 mg/L), and depression. In both trials, TT treatment led to a large, significant improvement in HRQOL compared with usual care (Cohen's d = 1.19; P < .001). Receiving a statin for systemic inflammation and oral corticosteroid for eosinophilic airway inflammation was associated with the largest HRQOL improvements. Treatments for exercise intolerance, anxiety, and obesity were associated with smaller improvements in HRQOL. Conclusions: This study contributes to identifying clinically impactful TTs by showing that TTs across pulmonary, extrapulmonary, and behavioral domains were associated with HRQOL impairment and treatment response.]]> Thu 08 Jun 2023 15:21:50 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38890 Fri 25 Feb 2022 17:03:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54670 Fri 08 Mar 2024 11:32:27 AEDT ]]>